Sanofi-Aventis To Expand Operations In China
This article was originally published in PharmAsia News
Executive Summary
France's Sanofi-Aventis plans to use a new agreement with the Shanghai Institute for Biological Sciences to expand its research and development facility and step up that work in China. The agreement calls for a focus on discovering and developing drugs to treat cancer, diabetes, and problems of the nervous systems. The agreement in Shanghai coincides with completion by the end of this year of the firm's biometrics center in Beijing, aimed at providing support for global and local clinical trials. (Click here for more
You may also be interested in...
Pharmaceutical Industry Examines China R&D Strategy Amidst Financial Crisis
In the face of sliding profit margins and imminent drug patent expiry, multinational drug firms are seeking different avenues such as investing in or buying biotech firms to acquire new drugs. Sanofi-Aventis does not discount such possibilities but advocates collaboration as a better model to retain talent and technology. The company recently established a partnership with the Shanghai Institute for Biological Sciences (PharmAsia News Oct. 23, 2008) to cooperate with local academic institutes instead of setting up its own R&D center. According to Sanofi officials, the firm's R&D investment this year will be flat or even decrease slightly. (Click here for more - Chinese Language)
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.